Previous 10 | Next 10 |
2023-05-03 13:56:00 ET NovoCure ( NASDAQ: NVCR ) is scheduled to announce Q1 earnings results on Thursday, May 4th, before market open. The consensus EPS Estimate is -$0.34 (-750.0% Y/Y) and the consensus Revenue Estimate is $127.93M (-7.0% Y/Y). Over the last 1 year, ...
Novocure (NASDAQ: NVCR) today announced the results of the LUNAR phase 3 clinical trial in metastatic, non-small cell lung cancer (NSCLC) will be presented for the first time at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from June 2 to June 6. ...
Novocure (NASDAQ: NVCR) today announced 27 presentations on Tumor Treating Fields (TTFields) will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14 to 19 in Orlando, Florida. The research described in the presentations includes real-w...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2023 on Thursday, May 4, 2023, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three mo...
Novocure (NASDAQ: NVCR) today announced that Kristin Stafford has been elected to Novocure’s Board of Directors. “We look forward to welcoming Ms. Stafford to our board of directors,” said William Doyle, Novocure’s Executive Chairman. “Her broad expertise in...
2023-03-27 05:22:43 ET Summary NovoCure has seen strong growth over the past decade but is unable to post profits with large sums invested into the pipeline. After softer sales momentum, pipeline conversion to other cancer types is necessary to drive appeal. Expectations have ...
2023-03-22 07:55:00 ET The use of bioelectronic devices for pain management is a growing industry expected to continue expanding in the coming years. Bioelectronic devices, also known as […] For further details see: Top Stocks in the Medical Device Boom (SWAV, EMED, NVCR, IRTC, M...
2023-03-20 15:02:25 ET Summary NovoCure focuses on promoting Optune and Optune Lua, FDA-approved devices utilizing Tumor Treating Fields (TTFields) technology to target and destroy cancer cells. The LUNAR study in non-small cell lung cancer (NSCLC) met its primary endpoint, showin...
Novocure (NASDAQ: NVCR) today announced the 5 th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The program represents a joint effort with the American Association for Cancer Research (AACR) to promote and support innovative research on Tumor Treating Fields (TTFields...
Novocure ( NASDAQ: NVCR ) said its device Optune will get reimbursement and was available with temozolomide (TMZ) in France to treat adult patients with newly diagnosed glioblastoma (GBM), a type of brain cancer. The company noted that the order registering Optune on th...
News, Short Squeeze, Breakout and More Instantly...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three...
2024-06-13 14:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-04 10:45:03 ET Wells Fargo analyst issues NEUTRAL recommendation for NVCR on June 4, 2024 09:01AM ET. The previous analyst recommendation was Neutral. NVCR was trading at $24.055 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...